In investigating the usefulness of MS-OVA to induce potent CD8+ T cell responses in a therapeutic tumor model, we observed that while MS-OVA could induce antigen-specific CD8+ T cells in tumor-bearing mice which resulted in a decrease in tumor burden and even a short tumor-free period, tumor recurrence occurred and mice eventually succumbed to tumor burden. Here, CD8A is linked to neoplasm.